<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities and Exchange Act of 1934
Date of Report: (Date of earliest event reported): January 2, 2001
TEXAS BIOTECHNOLOGY CORPORATION
(Exact name of registrant as specified in its charter)
<TABLE>
<S> <C> <C>
DELAWARE 1-12574 13-3532643
(State of Incorporation) (Commission File Number) (IRS Employer Identification No.)
----------------------------------------------------------------------------------------------------------------------
</TABLE>
7000 FANNIN, 20TH FLOOR
HOUSTON, TEXAS 77030
(Address of Registrant's principal executive offices)
(713) 796-8822
(Registrant's telephone number, including area code)
(NOT APPLICABLE)
(Former name or former address, if changed since last report)
<PAGE> 2
ITEM 5. OTHER EVENTS
On January 5, 2001, we announced that we have received approximately $21.7
million from the exercise of approximately 2,570,000 of our publicly traded
Common Stock Warrants (AMEX:TXB/WS), (the "Warrants"). The Warrants expired at
5:00 PM, eastern standard time, on Sunday, December 31, 2000 and were
exercisable until Tuesday, January 2, 2001. The exercise price of the Warrants
was $8.44 with one Warrant equal to one share of Texas Biotechnology stock.
There were approximately 3.8 million Warrants outstanding.
As a result of the exercise of these Warrants, we currently have over $110
million in cash, cash equivalents and investments, and approximately 43.6
million common shares outstanding.
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: January 5, 2001 TEXAS BIOTECHNOLOGY CORPORATION
/s/ Stephen L. Mueller
---------------------------------------
Stephen L. Mueller
Vice President, Finance and
Administration, Secretary and Treasurer
